US youth study finds no increased substance-use risk after ADHD medication…

Longitudinal patterns of attention-deficit/hyperactivity disorder medication use and subsequent incident substance use among US youth.

Journal of child psychology and psychiatry, and allied disciplines • • Moderately Relevant
🤖

AI Summary

This longitudinal observational study asked whether starting or stopping ADHD medication was associated with later substance use among US youth with a parent-reported ADHD diagnosis. It analyzed 4,700 observations from 2,140 young people ages 12–17 in nationally representative data collected from 2013 to 2023, using propensity score weighting to account for pre-existing differences. The researchers compared medication initiation with no medication use, and discontinuation with continued use, then assessed incident use of alcohol, nicotine or tobacco, e-cigarettes, cannabis, and other drugs one year later.

Neither starting nor stopping ADHD medication was associated with a different risk of subsequent incident substance use in the comparisons reported. The findings add evidence that these medication-use patterns were not related to increased substance-use risk in this population. Because this was an observational study, it cannot establish that medication patterns cause—or prevent—substance use; this abstract-based summary also cannot address details beyond those reported in the abstract.

💡 Key Findings

1
Among youth with parent-reported ADHD, starting ADHD medication was not associated with different subsequent incident substance-use risk compared with no medication use.
High
80%
2
Stopping ADHD medication was not associated with different subsequent incident substance-use risk compared with continuing medication.
High
80%
3
The outcomes included incident cannabis use alongside alcohol, nicotine or tobacco, e-cigarette, and other drug use, assessed one year later.
High
90%

📄 Original Abstract

BACKGROUND: Understanding potential substance use risks or protection associated with ADHD medication use over time among US youth with ADHD has clinical and public health importance. Using longitudinal nationally representative data and accounting for pre-existing differences in youth can shed light on these associations. METHODS: This study used longitudinal prospective data from the Population Assessment of Tobacco and Health Study (2013/14-2023). Analyses included youth ages 12-17 with a parent-reported history of an ADHD diagnosis by a doctor, nurse, or health professional (n = 4,700 observations; n = 2,140 unique individuals). Using propensity score weighting to account for pre-exposure differences, the effect of ADHD medication initiation compared to no ADHD medication use and the effect of ADHD medication discontinuation compared to continuation on five incident substance use outcomes (alcohol, nicotine/tobacco, e-cigarettes, cannabis, other drugs) 1 year later were examined. RESULTS: Among youth with parent-reported ADHD, those who initiated ADHD medication did not differ from youth who did not use ADHD medication in subsequent incident substance use risk (adjusted odds ratios ranged from 0.94 to 1.36). Similarly, those who discontinued ADHD medication did not differ from youth who continued ADHD medication in subsequent risk for incident substance use (adjusted odds ratios ranged from 0.98 to 1.02). CONCLUSIONS: These results add to the evidence that ADHD medication use initiation and medication discontinuation patterns are not related to an increased risk for incident substance use among US youth. This study highlights the importance of considering baseline differences between youth when considering the effect of ADHD medication on future substance use risk.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.